Nimmo M J, Merrick M V, Millar A M
Br J Radiol. 1985 Jul;58(691):635-6. doi: 10.1259/0007-1285-58-691-635.
We have compared the cost of providing routine lung ventilation scintigraphy using 127Xe with other radioactive gases in 100 patients. The physical properties of 127Xe permit a logical imaging sequence where a ventilation study is only carried out if indicated by perfusion scintigraphy which is performed first. With 133Xe, all patients must be ventilated prospectively, or a preselection carried out based on radiographic appearances at the time of imaging. This results in a greater number of ventilation studies than with 127Xe. Despite the greater cost per study of 127Xe, the overall cost of providing a routine diagnostic service with this gas is no more than that of using 133Xe in selected patients. The cost of ventilating all patients prospectively with 133Xe is considerably greater than using 127Xe only when indicated by abnormal perfusion images. If ventilation imaging is to be available at all times, either isotope of xenon costs very much less than 81Krm. We conclude that 127Xe is the radiopharmaceutical of choice for routine lung ventilation scintigraphy.
我们比较了100例患者使用127Xe进行常规肺通气闪烁扫描与使用其他放射性气体的成本。127Xe的物理特性允许采用一种合理的成像流程，即只有在首先进行的灌注闪烁扫描显示有必要时才进行通气研究。使用133Xe时，所有患者都必须前瞻性地进行通气，或者根据成像时的放射学表现进行预选。这导致通气研究的数量比使用127Xe时更多。尽管127Xe每次研究的成本更高，但使用这种气体提供常规诊断服务的总成本并不高于在选定患者中使用133Xe的成本。前瞻性地对所有患者使用133Xe进行通气的成本，比仅在灌注图像异常时使用127Xe的成本要高得多。如果要随时进行通气成像，任何一种氙同位素的成本都远低于81Krm。我们得出结论，127Xe是常规肺通气闪烁扫描的首选放射性药物。
